25,901 results match your criteria Radiation Therapy Prostate Cancer


Comparison of multiparametric MRI-based and transrectal ultrasound-based preplans with intraoperative ultrasound-based planning for low dose rate interstitial prostate seed implantation.

J Appl Clin Med Phys 2019 Apr 19. Epub 2019 Apr 19.

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.

Purpose: Transrectal ultrasound images are routinely acquired for low dose rate (LDR) prostate brachytherapy dosimetric preplanning (pTRUS), although diagnostic multiparametric magnetic resonance imaging (mpMRI) may serve this purpose as well. We compared the predictive abilities of TRUS vs MRI relative to intraoperative TRUS (iTRUS) to assess the role of mpMRI in brachytherapy preplanning.

Materials And Methods: Retrospective analysis was performed on 32 patients who underwent iTRUS-guided prostate LDR brachytherapy as either mono- or combination therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acm2.12592DOI Listing

Prostate Specific Antigen Nadir After Radical Cystoprostatectomy in Patients With Benign Prostatic Tissue: A Benchmark To Define Biochemical Recurrence after Radical Prostatectomy.

Urol J 2019 Apr 20. Epub 2019 Apr 20.

Department of Urology, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Purpose: Biochemical failure after radical prostatectomy has been defined based on retrospective studies in men who underwent RP for localized prostate cancer. Nevertheless, retrospective strategy and possibility of extra-prostatic extension overshadowed the accurateness of the aforementioned cut-off value. To define a more precise PSA nadir value, we estimated serum PSA after cystoprostatectomy in cases with bladder urothelial cancer and no evidence of prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22037/uj.v0i0.4551DOI Listing
April 2019
1 Read

Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study.

Int J Radiat Oncol Biol Phys 2019 Apr 16. Epub 2019 Apr 16.

Sunnybrook Odette Centre; Department of Radiation Oncology, University of Toronto. Electronic address:

Purpose: HDR brachytherapy boost plus external beam radiotherapy is an established option for intermediate risk prostate cancer (PCa). SBRT boost can potentially mimic HDR boost, and could be a viable alternative. Here we report the long-term outcomes of a phase I dose-escalation trial of single-fraction SBRT boost. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.04.006DOI Listing

Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis.

Int J Surg 2019 Apr 16. Epub 2019 Apr 16.

Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address:

Background: Although androgen deprivation therapy with or without chemotherapy are currently the mainstay of therapy for metastatic prostate cancer, accumulating data suggested the survival benefits from definitive local therapy such as radical prostatectomy or radiation therapy. Hence, this network meta-analysis was aimed to provide a hierarchy of different therapeutic regimens for mPCa.

Methods: Relevant studies were retrieved comprehensively by searching the online databases of PubMed, EMBASE and Web of Science, published before July 1st, 2018. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S17439191193008
Publisher Site
http://dx.doi.org/10.1016/j.ijsu.2019.04.006DOI Listing
April 2019
1 Read

Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.

PLoS One 2019 19;14(4):e0215582. Epub 2019 Apr 19.

Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Introduction: Brachytherapy is a well-established treatment of localized prostate cancer. Few studies have documented long-term results, specifically biochemical progression-free survival (bPFS) in men with brachytherapy alone, with or without short-term androgen deprivation therapy (ADT), or in combination with external beam radiotherapy (EBRT). Our aim was to analyze long-term bPFS of brachytherapy treated patients. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215582PLOS

Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS).

Front Oncol 2019 2;9:217. Epub 2019 Apr 2.

Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Newcastle, NSW, Australia.

To report feasibility, early toxicity, and PSA kinetics following gantry-based, stereotactic radiotherapy (SBRT) boost within a prospective, phase 2, multicenter study (PROMETHEUS: ACTRN12615000223538). Patients were treated with gantry-based SBRT, 19-20 Gy in two fractions delivered 1 week apart, followed by conventionally fractionated IMRT (46 Gy in 23 fractions). The study mandated MRI fusion for RT planning, rectal displacement, and intrafraction image guidance. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2019.00217/
Publisher Site
http://dx.doi.org/10.3389/fonc.2019.00217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454110PMC
April 2019
1 Read

Volumetric modulated arc therapy planning based on virtual monochromatic images: Effect of inaccurate CT numbers on dose distributions.

Phys Med 2019 Apr 29;60:83-90. Epub 2019 Mar 29.

Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.

Purpose: Though virtual monochromatic images (VMIs) at low energy levels can improve image quality, the measured Hounsfield unit (HU) values can be inaccurate. We assessed the dosimetric error due to inaccurate HU estimation in volumetric modulated arc therapy (VMAT) planning.

Methods: Based on the VMIs at 50 keV (VMI), 77 keV (VMI) and single-energy CT (SECT) image for a phantom with different sizes, lookup tables (LUT and LUT) were created. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S11201797193006
Publisher Site
http://dx.doi.org/10.1016/j.ejmp.2019.03.022DOI Listing
April 2019
1 Read

Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.

Prostate Cancer Prostatic Dis 2019 Apr 17. Epub 2019 Apr 17.

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Background: This study aims to assess the effect of statin therapy on outcomes among men managed with active surveillance.

Methods: This is a retrospective cohort study evaluating 635 men managed with active surveillance from 2005 to 2015 at a large, academic medical center. The primary endpoints of analyses are disease reclassification (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0147-0DOI Listing
April 2019
1 Read

Oligometastatic Prostate Cancer.

Klin Onkol 2019 ;32(2):97-100

Background: With advancements in diagnostic techniques, oligometastatic prostate cancer is diagnosed in patients who were, in the past, considered to have localized disease. Moreover, evidence of the effectiveness of treatment intensification for this disease is increasing, focusing on primary tumors as well as metastatic lesions. Thus, we can delay the start of systemic palliative treatment and improve overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14735/amko201997DOI Listing
January 2019

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Eur Urol 2019 Apr 13. Epub 2019 Apr 13.

Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address:

Background: The role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases.

Objective: To assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.03.022DOI Listing
April 2019
2 Reads

A potent liver mediated mechanism for loss of muscle mass during androgen deprivation therapy.

Endocr Connect 2019 Apr 1. Epub 2019 Apr 1.

V Birzniece, School of Medicine, Western Sydney University, Penrith , Australia.

Context: Androgen deprivation therapy (ADT) in prostate cancer results in muscular atrophy, due to loss of the anabolic actions of testosterone. Recently we discovered that testosterone acts on the hepatic urea cycle to reduce amino acid nitrogen elimination. We hypothesize that ADT enhances protein oxidative losses by increasing hepatic urea production, resulting in muscle catabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-19-0179DOI Listing
April 2019
2 Reads

Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy.

Scand J Urol 2019 Apr 16:1-7. Epub 2019 Apr 16.

c Sahlgrenska Academy and University Hospital , University of Gothenburg , Gothenburg , Sweden.

Purpose: To evaluate the efficacy of a triple treatment strategy, including surgery, on high risk prostate cancer comparing long-term survival outcome with a cohort receiving standard radiotherapy with endocrine therapy.

Materials And Methods: This study compared two cohorts in survival outcomes, matched on the year of diagnosis and age. In both groups there was a curative intention to treat localized high-risk prostate cancer (one or more of Gleason score 8-10, PSA 20-50 or stage T3), diagnosed between 1995-2010, follow-up at the end of 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21681805.2019.1600580DOI Listing
April 2019
1 Read

Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy.

Prostate Cancer Prostatic Dis 2019 Apr 15. Epub 2019 Apr 15.

VA San Diego Health Care System, La Jolla, CA, USA.

Background: There is conflicting evidence regarding the association between androgen deprivation therapy (ADT) for prostate cancer (PC) and the risk of developing stroke and thromboembolic events. Our study evaluated the association between ADT use and development of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), and pulmonary embolism (PE) in a homogenous group of men with PC treated with definitive radiation therapy (RT) after controlling for multiple sources of confounding.

Methods: Observational cohort study of patients diagnosed with PC at the US Department of Veterans Affairs between 1 January 2001 and October 31, 2015 and treated with definitive RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0150-5DOI Listing
April 2019
1 Read

Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial.

BMJ Open 2019 Apr 14;9(4):e024872. Epub 2019 Apr 14.

Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia.

Introduction: A potential link exists between prostate cancer (PCa) disease and treatment and increased inflammatory levels from gut dysbiosis. This study aims to examine if exercise favourably alters gut microbiota in men receiving androgen deprivation therapy (ADT) for PCa. Specifically, this study will explore whether: (1) exercise improves the composition of gut microbiota and increases the abundance of bacteria associated with health promotion and (2) whether gut health correlates with favourable inflammatory status, bowel function, continence and nausea among patients participating in the exercise intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-024872DOI Listing
April 2019
1 Read

AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.

Int J Mol Sci 2019 Apr 3;20(7). Epub 2019 Apr 3.

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Current clinical challenges of prostate cancer management are to restrict tumor growth and prohibit metastasis. AICAR (5-aminoimidazole-4-carbox-amide-1-β-d-ribofuranoside), an AMP-activated protein kinase (AMPK) agonist, has demonstrated antitumor activities for several types of cancers. However, the activity of AICAR on the cell growth and metastasis of prostate cancer has not been extensively studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20071647DOI Listing
April 2019
1 Read

A six-degree-of-freedom robotic motion system for quality assurance of real-time image-guided radiotherapy.

Phys Med Biol 2019 Apr 15. Epub 2019 Apr 15.

ACRF Image X Institute, The University of Sydney Central Clinical School, University of Sydney, Sydney, New South Wales, AUSTRALIA.

In this study we develop and characterise a six degree-of-freedom (6DoF) robotic motion system for quality assurance of real-time image-guided radiotherapy techniques. The system consists of a commercially available robotic arm, an acrylic phantom with embedded Calypso markers, a custom base plate to mount the robot to the treatment couch, and control software implementing the appropriate sequence of transformations to reproduce measured tumour motion traces. The robotic motion system was evaluated in terms of the set-up and motion trace repeatability, static localization accuracy and dynamic localization accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6560/ab1935DOI Listing
April 2019
1 Read

The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.

Urology 2019 Apr 12. Epub 2019 Apr 12.

Specialist in Nuclear Medicine, Clinic of Nuclear Medicine, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.

Prostate-specific-membrane-antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (PCa). PSMA-expression correlates with higher serum levels of prostate-specific-antigen (PSA) and a higher Gleason Score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA PET/CT and PET/MRI. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00904295193034
Publisher Site
http://dx.doi.org/10.1016/j.urology.2019.04.004DOI Listing
April 2019
3 Reads

Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.

PLoS One 2019 15;14(4):e0215093. Epub 2019 Apr 15.

Vitus Prostate Center, Institut für Bildgebende Diagnostik, Offenbach, Germany.

Background: Irreversible Electroporation (IRE) is a novel image-guided tissue ablation technology that induces cell death via very short but strong pulsed electric fields. IRE has been shown to have preserving properties towards vessels and nerves and the extracellular matrix. This makes IRE an ideal candidate to treat prostate cancer (PCa) where other treatment modalities frequently unselectively destroy surrounding structures inducing severe side effects like incontinence or impotence. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215093PLOS
April 2019
1 Read

Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer.

Clin Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

Department of Radiology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Radiation-induced sarcoma is a rare complication of radiation therapy. We describe the incidental detection of a radiation-induced undifferentiated soft-tissue sarcoma with increased uptake on Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in a prostate cancer patient previously treated with surgery and external-beam radiotherapy. Results were confirmed by histological analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002592DOI Listing
April 2019
2 Reads

The Tumor Immune Contexture of Prostate Cancer.

Front Immunol 2019 28;10:603. Epub 2019 Mar 28.

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.

One in seven men in North America is expected to be diagnosed with prostate cancer (PCa) during their lifetime (1, 2). While a wide range of treatment options including surgery, radiation, androgen deprivation and chemotherapy have been in practice for the last few decades, there are limited treatment options for metastatic and treatment resistant disease. Immunotherapy targeting T-cell associated immune checkpoints such as CTLA-4, PD-L1, and PD-1 have not yet proven to be efficacious in PCa. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00603
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447686PMC
March 2019
2 Reads

Validation of Three-dimensional Electronic Portal Imaging Device-based PerFRACTION™ Software for Patient-Specific Quality Assurance.

J Med Phys 2019 Jan-Mar;44(1):16-20

Department of Medical Physics, BC Cancer Agency-Abbotsford Cancer Center, British Columbia, Canada.

Purpose: PerFRACTION™ is a three-dimensional (3D) electronic portal imaging device-based dosimetry software. To validate the software, three phantoms with different inserts (2D array, ionization chamber, and inhomogeneity materials) were constructed to evaluate point dose and fluence map.

Materials And Methods: Phantoms underwent independent computed tomography simulation for planning and received repetitive fractions of volumetric modulated arc therapy, simulating prostate treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmp.JMP_76_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438053PMC
April 2019
1 Read

A Prospective Study on F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

J Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

BC Cancer, Canada.

F-DCFPyL, a prostate specific membrane antigen targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity and impact on patient management of F-DCFPyL in the settings of biochemical recurrence of prostate cancer. Subjects with prostate cancer and biochemical recurrence post radical prostatectomy/curative intent radiotherapy were included in this prospective study. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.119.226
Publisher Site
http://dx.doi.org/10.2967/jnumed.119.226381DOI Listing
April 2019
2 Reads

Low-Dose-Rate and High-Dose-Rate Brachytherapy for Localized Prostate Cancer in ABO-Incompatible Renal Transplant Recipients.

Transplant Proc 2019 Apr 9;51(3):774-778. Epub 2019 Jan 9.

Division of Urology, Department of Regenerative & Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.

Background: Brachytherapy is one of the standard treatments for localized prostate cancer (CaP). However, the feasibility of brachytherapy for renal transplant recipients (RTRs) is still uncertain.

Materials And Methods: Between August 2007 and March 2018, all patients who had undergone low-dose-rate (LDR) brachytherapy or high-dose-rate (HDR) brachytherapy for clinically localized CaP at our institution were retrospectively identified (n = 394). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.10.027DOI Listing
April 2019
1 Read

Safety of SBRT in post TURP prostate cancer patients: A propensity score matched pair analysis.

Pract Radiat Oncol 2019 Apr 9. Epub 2019 Apr 9.

Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India.

Purpose: To determine the genitourinary (GU) toxicity outcomes in prostate cancer patients treated with stereotactic body radiotherapy (SBRT) who have undergone a prior transurethral resection of prostate (TURP) and compare it to a similar nonTURP cohort.

Materials And Methods: Fifty prostate cancer patients who had undergone a single TURP, had a good baseline urinary function and were subsequently treated with SBRT were chosen from a prospectively maintained database. These were propensity score matched to a similar non-TURP cohort treated during the same time period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2019.04.003DOI Listing
April 2019
4 Reads

Robotic-assisted perineal versus transperitoneal radical prostatectomy: A matched-pair analysis.

Turk J Urol 2019 Apr 3. Epub 2019 Apr 3.

Department of Urology, Health Sciences University, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey.

Objective: We compared the outcomes of robotic-assisted radical perineal prostatectomy (r-PRP) versus robotic-assisted transperitoneal laparoscopic radical prostatectomy (RARP).

Material And Methods: Between November 2016 and September 2017 in our center, 40 patients underwent r-PRP, and 40 patients underwent RARP. All patients also underwent multiparametric magnetic resonance imaging (mpMRI) to exclude the cases with locally advanced disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/tud.2019.98254DOI Listing
April 2019
1 Read

Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies.

Int Urol Nephrol 2019 Apr 12. Epub 2019 Apr 12.

Division of Urology, University of Cincinnati Cancer Institute, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0589, Cincinnati, OH, 45267, USA.

Biochemical recurrence of prostate cancer occurs in 25-33% of patients who undergo radiation therapy (RT). Unfortunately, greater than 90% of patients with radiation recurrence undergo androgen deprivation therapy (ADT), despite the detrimental side effect profile and the lack of supporting evidence for ADT use in local recurrence. In patients who experience recurrence after treatment with RT, options for treatment include salvage radical prostatectomy (SRP), salvage cryotherapy (SCT), salvage brachytherapy (SBT), and high-intensity focused ultrasound (HIFU). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-019-02114-4DOI Listing
April 2019
1 Read

Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan.

Actas Urol Esp 2019 Apr 8. Epub 2019 Apr 8.

Servicio de Urología, MD Anderson Cancer Center-Madrid, Madrid, España.

Introduction And Objectives: Nodal prostate cancer recurrence is a challenging scenario. Current guidelines recommend the use of androgen deprivation therapy, tailored treatment or clinical trials. We studied the impact of Salvage lymph node dissection in selected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acuro.2018.07.004DOI Listing
April 2019
1 Read

Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis.

PLoS One 2019 11;14(4):e0215057. Epub 2019 Apr 11.

Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

Purpose: To investigate whether whole pelvic radiotherapy (WPRT) improves biochemical relapse-free survival (bRFS) vs. prostate bed radiotherapy (PBRT) in prostate cancer patients receiving salvage radiotherapy (SRT) after radical prostatectomy.

Methods: Data from patients with prostate cancer who underwent SRT for biochemical recurrence between 2005 and 2012 in two academic institutions were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215057PLOS
April 2019
2 Reads

An Extended Dose-Volume Model in High Dose-Rate Brachytherapy - Using Mean-Tail-Dose to Reduce Tumour Underdosage.

Med Phys 2019 Apr 11. Epub 2019 Apr 11.

Radiation Physics, Department of Medical and Health Sciences, Linkӧping University, SE-58185, Linkӧping, Sweden.

Purpose: High dose-rate brachytherapy is a method of radiotherapy for cancer treatment in which the radiation source is placed within the body. In addition to give a high enough dose to a tumour, it is also important to spare nearby healthy organs (organs at risk). Dose plans are commonly evaluated using so-called dosimetric indices; for the tumour, the portion of the structure that receives a sufficiently high dose is calculated, while for organs at risk it is instead the portion of the structure that receives a sufficiently low dose that is of interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.13533DOI Listing
April 2019
2 Reads

Quality assurance of non-coplanar, volumetric-modulated arc therapy employing a C-arm linear accelerator, featuring continuous patient couch rotation.

Radiat Oncol 2019 Apr 11;14(1):62. Epub 2019 Apr 11.

Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Purpose: To perform quality assurance of non-coplanar, volumetric-modulated arc therapy featuring continuous couch rotation (CCR-VMAT) using a C-arm linear accelerator.

Methods: We planned and delivered CCR-VMAT using the TrueBeam Developer Mode. Treatment plans were created for both a C-shaped phantom and five prostate cancer patients using seven CCR trajectories that lacked collisions; we used RayStation software (ver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-019-1264-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458733PMC

Long noncoding RNA GAS5 modulates α-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cells.

Biomed Pharmacother 2019 Apr 1;112:108656. Epub 2019 Mar 1.

Department of Urology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.

Radiotherapy is an adjuvant treatment of surgery in prostate cancer, while radioresistance has been the challenge of treatment. It has been reported that α-Solanine exhibits anti-cancer activity and enhances the chemo- and radio-sensitivity in several human cancers, whereas the role of α-Solanine on radiosensitivity to PCa remains to be uncovered yet. We found α-Solanine decreased cell viability in human PCa cells rather than normal prostate epithelial cells in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108656DOI Listing
April 2019
2 Reads

Impact of body-mass factors on setup displacement during pelvic irradiation in patients with lower abdominal cancer.

Radiol Oncol 2019 Apr 5. Epub 2019 Apr 5.

Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.

Background The aim of the study was investigate the impact of body-mass factors (BMF) on setup displacement during pelvic radiotherapy in patients with lower abdominal cancers. Patients and methods The clinical data of a training cohort composed of 60 patients with gynecological, rectal, or prostate cancer were analyzed. The daily alignment data from image-guided radiotherapy (IGRT) were retrieved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/raon-2019-0017DOI Listing
April 2019
2 Reads

Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care.

Prostate Cancer Prostatic Dis 2019 Apr 9. Epub 2019 Apr 9.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Advances in radiation technology have transformed treatment options for patients with localized prostate cancer. The evolution of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) have allowed physicians to spare surrounding normal organs and reduce adverse effects. The introduction of proton beam technology and its physical advantage of depositing its energy in tissue at the end-of-range maximum may potentially spare critical organs such as the bladder and rectum in prostate cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0140-7DOI Listing
April 2019
1 Read

Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.

Clin Exp Metastasis 2019 Apr 8. Epub 2019 Apr 8.

Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, The Key Laboratory of Nephropathy and the Kidney Disease Immunology Laboratory, The Third Grade Laboratory, 79 Qingchun Road, Hangzhou, Zhejiang, China.

Adjuvant therapy with bisphosphonates in prostate cancer is effective in improving bone mineral density and thus reducing fractures and skeletal-related events. We analyzed the effect of bisphosphonates on overall survival (OS) in subgroups of patients with prostate cancer. A systematic literature search was conducted of the PubMed database and the bibliographies of related studies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10585-019-09963-4
Publisher Site
http://dx.doi.org/10.1007/s10585-019-09963-4DOI Listing
April 2019
1 Read

Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials.

Int J Radiat Oncol Biol Phys 2019 Apr 5. Epub 2019 Apr 5.

Cedars-Sinai Medical Center, Los Angeles, CA.

Purpose: To validate if prostate specific antigen (PSA) level after neoadjuvant androgen suppression (neoAS) is associated with long-term outcome after neoAS and external radiation therapy (RT) with concurrent short-term AS in prostate cancer patients.

Methods: 2404 patients treated with neoAS prior to RT and concurrent AS (without post-RT AS) were pooled from trials A, B, C, and D. Multivariable models were used to test associations between the pre-specified dichotomized post-neoAS, pre-RT PSA (≤0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.03.049DOI Listing
April 2019
2 Reads

Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Int J Radiat Oncol Biol Phys 2019 Apr 5. Epub 2019 Apr 5.

University of Michigan, Department of Radiation Oncology. Electronic address:

Purpose: Utilization of stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer is increasing. Guidelines and payers variably support the use of prostate SBRT. We therefore sought to systematically analyze biochemical recurrence-free survival (bRFS), physician-reported toxicity, and patient-reported outcomes following prostate SBRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.03.051DOI Listing
April 2019
2 Reads

Androgens and depression: a review and update.

Authors:
Kevin T Nead

Curr Opin Endocrinol Diabetes Obes 2019 Apr 4. Epub 2019 Apr 4.

Department of Radiation Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Purpose Of Review: The aim of this study is to summarize recently published literature examining androgens and depression.

Recent Findings: The impact of androgen levels, androgen replacement therapy and pharmacologic androgen deprivation on depression and depressive symptoms remain active areas of investigation. Recent publications support the finding that testosterone replacement therapy in men with low testosterone may improve depression, and that androgen deprivation therapy in men with prostate cancer may contribute to depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MED.0000000000000477DOI Listing
April 2019
2 Reads

Multimodal treatment for high risk locally advanced prostate cancer following radical prostatectomy and extended lymphadenectomy: results of a prospective cohort study with high-dose intensity-modulated radiation therapy, concurrent docetaxel and long-term androgen deprivation therapy.

Minerva Urol Nefrol 2019 Apr 5. Epub 2019 Apr 5.

Department of Radiotherapy Oncology, National Cancer Institute CRO, Aviano, Pordenone, Italy.

Background: To prospectively evaluate the safety and oncologic outcomes of multimodal treatment in high risk-locally advanced prostate cancer patients (PCa).

Methods: High risk-locally advanced prostate cancer patients without distant metastases before radical prostatectomy (RP) were included. Adjuvant High-dose intensity-modulated radiation therapy (IMRT) with concurrent Docetaxel and long-term ADT were started after 3-6 months from RP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0393-2249.19.03388-5DOI Listing
April 2019
1 Read

Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.

Med Dosim 2019 Apr 4. Epub 2019 Apr 4.

Medical Physics Unit, "Giovanni Paolo II" Foundation, Catholic University of Sacred Heart, Campobasso, Italy.

Aim: Radical radiotherapy of prostate cancer requires a relatively high dose to achieve an optimal tumor control probability and a reduced dose to the critical structures related to the sexual function (S_OARs) in order to avoid erectile dysfunction. The aim of this study was to perform a planning feasibility analysis of a 3-level dose prescription with Simultaneous Integrated Boost (SIB) on the dominant intraprostatic lesion (DIL) and with S_OARs sparing.

Material And Methods: Twelve patients with clinically localized intermediate risk prostate cancer were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meddos.2019.01.008DOI Listing
April 2019
1 Read

External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort.

Eur Urol 2019 Apr 5. Epub 2019 Apr 5.

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

The impact of biochemical recurrence (BCR) after radical treatment of prostate cancer on oncological outcomes remains unclear. A new European Association of Urology BCR risk stratification (low and high risk) has been proposed. To validate these risk groups, we retrospectively analyzed data for 1125 post-radical prostatectomy (RP) BCR patients (surgery between 1992 and 2006). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.03.016DOI Listing
April 2019
2 Reads

Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review.

World J Urol 2019 Apr 6. Epub 2019 Apr 6.

Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, C.so Bramante 88/90, 10100, Turin, Italy.

Purpose: Salvage radical prostatectomy (sRP) represents a curative option for prostate cancer (PCa) biochemical recurrence (BCR) after radiation therapy (RT). In this review, we aimed to outline the contemporary results and use of sRP.

Methods: A web search was performed on the Ovid platform using Embase and Medline databases from January 2010 using pre-defined search terms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02749-zDOI Listing
April 2019
2 Reads

Preclinical Characterization of Y-NM600 in a variety of murine and human cancer tumor models.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

University of Wisconsin - Madison, United States.

We characterize the in vivo biodistribution and tumor selectivity of Y-NM600, a theranostic alkylphosphocholine radiometal chelate with broad tumor selectivity, in a variety of preclinical cancer models. Mice bearing flank tumors (representative of lung, pancreatic, prostate, liver, skin, and lymphoid cancers) were injected intravenously (IV) with 9.25 MBq of Y-NM600 and imaged longitudinally over 4-5 days using microPET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.224808DOI Listing
April 2019
2 Reads

F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

Emory University, United States.

We evaluated F-fluciclovine uptake parameters that correlate with true positivity for local recurrence in non-prostatectomy treated patients. Twenty-one patients (prostate-specific antigen 7.4±6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.227033DOI Listing
April 2019
3 Reads

Health Technology Assessment of Carbon-ion Beam Radiotherapy: A Systematic Review of Clinical Effectiveness and Safety for 54 Oncological Indications in 12 Tumour Regions.

Anticancer Res 2019 Apr;39(4):1635-1650

Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.

Background/aim: Due to the unique physical dose distribution of carbon-ion radiotherapy (CIRT), CIRT can be regarded as a novel tumour irradiation technique - potentially advantageous for various tumour types. Yet it is unclear in how far, superiority or inferiority can be claimed when comparing CIRT to standard irradiation. This study aimed to assess the scientific evidence regarding the effectiveness and safety of CIRT. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13269DOI Listing
April 2019
5 Reads

Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer.

Cancer Res 2019 Apr 5. Epub 2019 Apr 5.

Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine

Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. Transcriptome analysis of multiple prostate cancer models identified CXCR7, an atypical chemokine receptor, as one of the most upregulated genes in enzalutamide-resistant cells. AR directly repressed CXCR7 by binding to an enhancer 110kb downstream of the gene and expression was restored upon androgen deprivation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-2812DOI Listing
April 2019
3 Reads

Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 years and Older with Non-Metastatic Prostate Cancer? - National Survey.

J Geriatr Oncol 2019 Apr 2. Epub 2019 Apr 2.

Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Ontario, Canada.

Purpose: Clinical judgement may not be sufficient to detect relevant problems in older cancer patients. We investigated what Geriatric Assessment tools (GA) are used by Canadian radiation oncologists (CROs) to treat non-metastatic prostate cancer patients aged 80 years and older.

Methods: A 27-item cross-sectional survey was developed with input from a multidisciplinary team and distributed electronically to Genitourinary (GU) CROs via LimeSurvey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.01.015DOI Listing
April 2019
2 Reads

Automatizing a nonscripting TPS for optimizing clinical workflow and reoptimizing IMRT/VMAT plans.

Med Dosim 2019 Apr 2. Epub 2019 Apr 2.

Servicio de Dosimetría y Radioprotección, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

The purpose of this study was to design a toolkit that interacts with the Monaco (Elekta AB, Stockholm, Sweden) treatment planning system (TPS) for optimization of intensity-modulated radiation therapy and volumetric-modulated arc therapy without the need for a dedicated application programming interface. Successful inverse planning of radiotherapeutic treatment depends on the tweaking of many parameters; a tool was thus needed to explore these parameters more exhaustively without significantly increasing planning time. The software that we used was based on an open-source library that mimics human interaction with Microsoft Windows applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meddos.2019.02.006DOI Listing
April 2019
1 Read